menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Lilly signs $140M upfront partnership with Radionetics in radiopharma play

    FIERCE BIOTECH

    Lilly Completes Acquisition of POINT Biopharma

    PR NEWSWIRE

    POINT Biopharma shareholders get long-awaited radioligand therapy data

    PRESS RELEASE

    Lantheus and POINT Biopharma Announce Positive Results from SPLASH Trial

    GLOBENEWSWIRE

    Deadline for Point investors as data meets Lilly`s expectations

    FIERCE BIOTECH

    Eli Lilly extends tender offer to buy Point Biopharma after low participation

    REUTERS

    Lilly Announces the Receipt of NRC Consent in Connection with POINT Biopharma

    PR NEWSWIRE

    POINT Biopharma Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Lilly enters radiopharmaceuticals with $1.4B Point Biopharma buy

    FIERCE BIOTECH

    POINT Biopharma and Athebio Announce Partnership

    GLOBENEWSWIRE

    POINT Biopharma Reports Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

    GLOBENEWSWIRE

    POINT Biopharma Expands Its Research with Next-Generation Isotopes

    GLOBENEWSWIRE

    POINT Biopharma, AdvanCell Partner to Develop Lead-212-Labeled Radioligand

    CONTRACT PHARMA

    Isotopia Molecular Imaging today announced the appointment of Todd Hockemeyer

    PR NEWSWIRE

    POINT Biop Announces Appointment of Dr. Bridget Martell to Board of Directors

    GLOBENEWSWIRE

    POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023

    GLOBENEWSWIRE

    POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

    GLOBENEWSWIRE

    POINT Biopharma Reports 1Q 2023 FYR Results and Provides Business Highlights

    GLOBENEWSWIRE

    POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting

    GLOBENEWSWIRE

    Lantheus & POINT Biopharma Announce FDA Grants Fast Track Designation f

    GLOBENEWSWIRE

    Eckert & Ziegler to Supply Point Biopharma with Actinium-225

    GLOBENEWSWIRE

    POINT Reports Fourth Quarter and Full Year 2022 Financial Results

    GLOBENEWSWIRE

    POINT Biopharma Confirms Clinical Supply for the 177Lu-PNT2002 SPLASH Trial

    GLOBENEWSWIRE

    POINT Biopharma to Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial

    GLOBENEWSWIRE

    POINT Biopharma Announces Closing of Agreements with Lantheus Holdings

    GLOBENEWSWIRE

    POINT Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555

    GLOBENEWSWIRE

    Lantheus pledges up to $2B for 2 of POINT`s radiopharmaceuticals

    FIERCEBIOTECH

    POINT Biopharma Reports 3Q 2022 Financial Results & Strategic Collaboration

    GLOBENEWSWIRE

    POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001

    GLOBENEWSWIRE

    POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares

    GLOBENEWSWIRE

    POINT Biopharma Prices Public Offering of Common Stock

    GLOBENEWSWIRE

    POINT Provides Updated Safety Data from PIII SPLASH Trial in mCRPC at ESMO 2022

    GLOBENEWSWIRE

    POINT Biopharma Announces Poster Presentation at ESMO Congress 2022

    FIRSTWORDPHARMA

    POINT Biopharma to Publish Abstract at ESMO Congress 2022

    GLOBENEWSWIRE

    POINT Biopharma Reports Second Quarter 2022 Financial Results

    GLOBENEWSWIRE

    POINT Biopharma to Host Investor Education Event on PNT2002

    GLOBENEWSWIRE

    POINT Biopharma to Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial

    POINTBIOPHARMA

    POINT Biopharma to Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program

    GLOBENEWSWIRE

    POINT Biopharma Reports First Quarter 2022 Financial Results

    GLOBENEWSWIRE

    POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002

    GLOBENEWSWIRE

    POINT Biopharma to Present Pan-Cancer FAP-Alpha Targeted Program at AACR

    GLOBENEWSWIRE

    POINT Biopharma Reports Fiscal 2021 Financial Results

    GLOBENEWSWIRE

    POINT Biopharma Confirms No Delays to SPLASH Trial

    GLOBENEWSWIRE

    POINT Biopharma to Host Dosimetry Investor Education Event on March 29, 2022

    GLOBENEWSWIRE

    POINT Biopharma Announces Abstract Publication of Dosimetry Data

    GLOBENEWSWIRE

    POINT Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

    GLOBENEWSWIRE

    POINT Biopharma Licenses Innovative Lu-177 Production Technology

    GLOBENEWSWIRE

    POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement

    GLOBENEWSWIRE

    POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement

    GLOBENEWSWIRE

    POINT Biopharma Releases New Data and Exercises Option

    GLOBENEWSWIRE

    POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH

    GLOBENEWSWIRE

    Convergent Therapeutics and Point Biopharma to Evaluate CONV 01-? + PNT2002

    PRNEWSWIRE

    Point Biopharma soars 8% amid team up with Convergent

    SEEKINGALPHA

    NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement

    BUSINESSWIRE

    POINT Biopharma Reports Second Quarter 2021 Financial Results

    GLOBENEWS WIRE

    POINT Biopharma Debuts as Publicly Traded Next-Gen Radiotherapeutics Company

    BIOSPACE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.